Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

Sanjaya SinghDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USACorrespondence[email protected]

Rachel R Kroe-BarrettDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Keith A CanadaDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Xiang ZhuDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Eliud SepulvedaDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Helen WuDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Yaqin HeDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Ernest L RaymondDepartment of Immunology; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Jennifer AhlbergDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Lee E FregoDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Laura M AmodeoDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Katrina M CatronDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

David H PreskyDepartment of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Jeffrey H HankeGlobal Head of Biotherapeutics Research; Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA

Your download is now in progress and you may close this window